ESMO 2021: Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer Patients in the US
ESMO 2021 real-world treatment patterns among patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Related Articles
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review – Beyond the Abstract
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Metastatic Hormone-sensitive Prostate Cancer Treatment, Docetaxel, Novel Hormonal Therapy (NHT), enzalutamide, apalutamide, abiraterone, androgen deprivation therapy (ADT).
Bone Health Management for Advanced Prostate Cancer – Fred Saad
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Bone Health Management for Advanced Prostate Cancer – Fred Saad Part…
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC – Neal Shore
Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the…
Testicular Cancer Survivors Find Community and Healing Through Foundation and Patient Summit – Connor O’Leary & Charles Freeman McCluskey
Zach Klaassen hosts a discussion with Connor O’Leary and Freeman McClusky, both testicular cancer survivors. They delve into the history and mission of Testicular Cancer…
How Mental Health Disorders Impact Treatment Decisions in Localized Prostate Cancer – Yaw Nyame & Joshua Cabral
Ruchika Talwar hosts Joshua Cabral and Yaw Nyame to explore the impact of mental health disorders on prostate cancer care. Their study, “Inequities in Definitive…
AUA Guidelines Provide Roadmap for Assessing Disease Burden and Personalizing Systemic Therapies in Metastatic Hormone Sensitive Prostate Cancer, Journal Club – Rashid Sayyid & Zachary Klaassen
Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the…
Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis – Beyond the Abstract
non-muscle invasive bladder cancer (NMIBC), transurethral resection of the bladder tumor (TURBT), Tumor T stage, cancer-specific survival (CSS) in patients with non-muscle invasive bladder cancer…
Update on Biomarkers in Renal Cell Carcinoma – David Braun
Pedro Barata and David Braun delve into the evolving landscape of biomarkers in renal cell carcinoma (RCC). Dr. Braun emphasizes the transition from histological analysis…
New Chinese Trial Shows Blue Light Cystoscopy Superior for Bladder Cancer Detection – Hongxian Zhang
Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection…
APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care – Silke Gillessen
Silke Gillessen discusses upcoming APCCC 2024 and delves into how the conference will tackle crucial topics from GU ASCO 2024, highlighting the dynamic field of…